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ABSTRACT
Objective To explore the reasons behind the recent
increase in antidepressant prescribing in the United
Kingdom.
Design Detailed retrospective analysis of data on general
practitioner consultations and antidepressant
prescribing.
Data sourceData were obtained from the general practice
research database, which contains linked anonymised
records of over 3 million patients registered in the UK.
Data were extracted for all new incident cases of
depression between 1993 and 2005.
Review methods Detailed analysis of general practitioner
consultations and antidepressant prescribing was
restricted to 170 practices that were contributing data for
the full duration of the study.
Results In total, 189851 people within the general
practice research database experienced their first
episode of depression between 1993 and 2005, of whom
150825 (79.4%) received a prescription for
antidepressants in the first year of diagnosis. This
proportion remained stable across all the years
examined. The incidence of new cases of depression rose
in young women but fell slightly in other groups such that
overall incidence increased then declined slightly (men:
7.83 cases per 1000 patient years in 1993 to 5.97 in
2005, women: 15.83 cases per 1000 patient years in
1993 to 10.06 in 2005). Antidepressant prescribing
nearly doubled during the study period—the average
number of prescriptions issued per patient increased
from 2.8 in 1993 to 5.6 in 2004. The majority of
antidepressant prescriptions were given as long term
treatment or as intermittent treatment to patients with
multiple episodes of depression.
Conclusions The rise in antidepressant prescribing is
mainly explained by small changes in the proportion of
patients receiving long term treatment. Previous clinical
guidelines have focused on antidepressant initiation and
appropriate targeting of antidepressants. To address the
costly rise in antidepressant prescribing, future research
and guidance needs to concentrate on appropriate long
term prescribing for depression and regular review of
medication.
BACKGROUND
Substantial increases in antidepressant prescribing
have been observed in the United Kingdom over the
past two decades. Data from the Prescription Pricing
Authority show that antidepressant prescribing inEng-
land increased by 36% to 7.3 million items per quarter
between 2000 and 2005, and costs increased by 20% to
£91 million (€100 million; $145 million) per quarter.1
Prescribing of selective serotonin reuptake inhibitors
increased by 45% during this period and accounted
for half of all prescriptions and costs for antidepressant
drugs. Further rises, predominantly in the prescription
of selective serotonin reuptake inhibitors, have
occurred since these data were released, although
costs have fallen since 2005 because several key
patents have expired.2 In addition, evidence exists for
rises in antidepressant prescribing since the middle of
the 1970s.3 These trends are not limited to the UK:
similar rises have been described in other Western
nations such as Australia and Canada.4-9
Various explanations have been proposed to deci-
pher these long term trends, including improved
adherence to guidelines—resulting in longer initial
courses of antidepressants—and a lower threshold for
prescribing. A study combining longitudinal data from
prescribing surveys and data from general practices in
Scotland explored four potential explanations:
increased incidence; increased prevalence; increased
care seeking behaviour by patients; and improved
identification of depression by general practitioners.10
Despite confirming the increase in antidepressant pre-
scribing, the authors were unable to find any changes
in incidence or prevalence of depression, or any
change in help seeking behaviour. Nor did general
practitioners record a higher number of diagnoses of
depression.
Another plausible explanation is that long term
repeat prescribing of antidepressants has increased in
recent years. A cross sectional survey of general
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practice records from 2002 and 2004 highlights the
relative importance of chronic prescribing.11 In this
study, depression and mixed anxiety and depression
accounted for 61% of all prescriptions for anti-
depressants. New prescriptions for antidepressant
medication initiated in primary care have very high
discontinuation rates,12 13 and, therefore, mainly com-
prise short courses. Nevertheless, depression and
mixed anxiety were associated with long term use of
antidepressants in this study, with an average duration
of five to seven years. The implication is that long term
prescriptions have a greater influence on average treat-
ment length than incident prescribing.
The general practice research database (GPRD) is an
internationally recognised resource that contains
linked anonymised primary care records of over 3mil-
lion patients registered in the UK. The database is
widely used for pharmacoepidemiological research
and allows follow-up of large cohorts of users of speci-
fic drugs.14
The objective of this study was to investigate using
the GPRD changes in the patterns of antidepressant
prescribing over time. We also aimed to investigate
whether thewidely reported increase in antidepressant
prescriptions in recent years is the result of any of the
following reasons: an increase in the incidence of new
cases of depression (which may reflect improved
recognition or lower thresholds for diagnosis); an
increase in the proportion of new cases of depression
for whom antidepressants are prescribed; an increase
in the duration of prescribing for new cases of depres-
sion (in line with guidelines recommending treatment
for four to six months after remission15); or an increase
in long term prescribing of antidepressants overall
(either repeated courses to treat recurrences or contin-
uous prescribing to prevent recurrence).
METHODS
We identified in the GPRD incident cases of new
depression that arose between 1993 and 2005. Patients
were included if they received a first ever anti-
depressant prescription for depression diagnosed up to
180 days before or 90 days after the prescribing event,
or received a first ever diagnosis of depression without
an associated prescription for antidepressants.
New practices joined the GPRD during data collec-
tion, so the denominator—that is, the number of
patients registered in the GPRD—varied from 1.5 mil-
lion in 1993 to amaximumof 3million in 2001, with an
approximate total of 29million registered patients over
the 13 year study. In order to better understand the
changes in the data, we restricted our detailed analysis
to practices that remained in the database throughout
the period of study and submitted data that met the
GPRDquality criteria.Althoughpatients can leave indi-
vidual practices, usingonly thedata fromthesepractices
will provide more stable interpretation of trends.
Patients entered into a cohort on the basis of the year
of their first ever diagnosis of depression and then
remained in the cohort for the remainder of the study
period. They may never have received a prescription
for antidepressants, had a single episode of treated
depression, had multiple episodes of depression, or
received continuous treatment for depression. The
cohort of patients being followed in 1993 comprised
the incident cases of first ever episode depression in
that year only, whereas the cohort in following years
included patients from previous years as well as the
incident cases that year. Once patients had entered
the cohort they then remained in the cohort until the
end of the study period or until they were transferred
out for other reasons (for example, death), while new
incident cases were continually added. Thus in later
years the total cohort included a mixture of incident
cases, prevalent cases, and new episodes occurring in
those who had entered the cohort previously.
We used patient years at risk as the denominator to
calculate the overall incidence of first episode of
depression. For example, someonewhowas registered
in the GPRD for only six months of the year would
contribute 0.5 years to the denominator. Prescribing
events were episodes of antidepressant prescribing,
regardless of prescription duration. Duration of pre-
scription was calculated using an algorithm described
in the detailed methods online.
To address our study questions and examine more
closely trends occurring within the cohort, we divided
patients into five pre-defined treatment pattern groups
on the basis of treatment in the five years following first
diagnosis (five year follow-up was possible only for
those diagnosed between 1993 and 2001). The five
pre-defined treatment pattern groups were:
 Chronic treatment: patients who received a
prescription in the year of first diagnosis and in
every year after that, for five years
 Intermittent treatment: patients who received a
prescription in the year of first diagnosis and at
least one subsequent year
 Short term treatment: patients who received a
prescription in the year of first diagnosis but not
in any subsequent years
 Delayed treatment: patients who received no
prescription in the year of first diagnosis but did
receive a prescription in any subsequent year up
to five years of follow-up
 No treatment: patients with depression who
never received a prescription within five years of
follow-up.
These five treatment pattern groups are mutually
exclusive—that is, each incident case could only fall
into one of the five groups followed up for a maximum
of five years from the year of their first diagnosis. Patient
data were included only when information for all five
years was available. The data analyses for this research
were undertaken using version 9.1 of the SAS System
for Windows (SAS Institute Inc; Cary, NC, USA).
RESULTS
Diagnostic events
The stable dataset included 170 practices and 1.7 mil-
lion registeredpatients. Patients in the stable cohort did
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not differ from the whole cohort in their age and sex
distribution. Within the stable cohort, 632 044 diag-
noses of depression were recorded. The top 20 most
frequently used diagnostic labels are listed in web
table A.
In total, 189 851 patients had their first diagnosis of
depression between 1993 and 2005. The top 20 most
common diagnostic labels according to patients’ first
ever diagnosis are listed in web table B. No major dif-
ferences were apparent between the whole cohort and
the stable practices in use of diagnostic labels; for
instance, the top 20 labels accounted for 97.3% of all
diagnoses in the whole cohort comparedwith 96.9% in
the stable practices.
Incidence of depression
Figure 1 illustrates the incidence of first episodes of
depression per 1000 patient years in the 170 stable
practices. In 1993, the incidence of new cases depres-
sion was around twice as high in women as in men
(9493/599 849 (15.8%) v 4573/584 049 (7.8%)). Over-
all incidence across each gender declined slightly
between 2001 and 2005 (men: 7.83 cases per 1000
patient years in 1993 to 5.97 in 2005, women: 15.83
cases per 1000 patient years in 1993 to 10.06 in 2005;
web table C).
Incidence rates were slightly higher in the whole
cohort than in the stable practices. For example, in
1993, the incidence in men was 9.3% for the whole
cohort compared with 7.8% in stable practices (6373/
683 586 and 4573/584 049, respectively), and in
females these values were 18.3% and 15.8%, respec-
tively (12 868/709 905 and 9493/599 849).
The data were then further divided into four age
bands to demonstrate the relation between age and
incidence of first episode of depression (figs 2 and 3;
web table C). These data show that the highest inci-
dence of the first episode of depression was in women
aged between 18 years and 30 years. Over the 13 year
period, the incidence in women in this age group rose
from23.8 per 1000 patient years in 1993 to peak at 37.7
per 1000 patient years in 2001, before falling again to
26.4 per 1000 patient years in 2005. Thus, the inci-
dence of new cases of depression rose in young
women but fell slightly in other groups such that over-
all incidence declined slightly.
Although the incidence in men was always lower
than that in women, the change over time in each age
group was similar. The highest incidence of first
depression was seen in the 18-30 years age group for
both men and women.
Prescribing events
The prescription data for the stable cohort consisted of
2 108 311 prescribing events among 153 931 patients.
We combined these data with the diagnosis data to
look at prescriptions specifically in patients who had
a diagnosis of depression. According to these com-
bined data, there were 2 093 737 prescribing events in
189 851 patients who were diagnosed as depressed. Of
those patients diagnosed as depressed, 153 914 (81.1%)
received at least one prescription for antidepressants.
The proportion of patients with depression who
received a prescription for an antidepressant in the
year of their first diagnosis was then examined (web
table D). The majority (150 825 (79.4%)) received a
prescription in the year of their first diagnosis. The pro-
portionwho received a prescription in the year of diag-
nosis was relatively constant at around 80%, then fell
slightly after 2002 to 74% in 2005. The proportion of
patientswho received ongoing prescriptions, however,
increased over the course of the study (web table D).
The proportion of patientswho remained on treatment
in the second year after diagnosis, for example,
increased from 40.6% in 1994 to peak at 51.4% in
2004 (4533/1159 and 6430/12 502, respectively).
This trendwas also observedwithin in the third, fourth,
and fifth year after diagnosis, although the magnitudes
were relatively smaller.
The average number of prescriptions issued per
patient in each year of the study period was then deter-
mined. The number of prescriptions rose from 2.8 per
patient in 1993 to 5.6 per patient in 2004. However, in
later years new patients were continually added so that
the cohort included a mixture of incident cases, preva-
lent cases, and new episodes occurring in those who
had entered the cohort previously. Therefore, the
increase in the number of prescriptions is likely to
have arisen from a change in the nature of the cohort
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Fig 1 | Incidence of first event of depression per 1000 patient
years in the 170 stable practices
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Fig 2 | Rate of diagnosis of first episode of depression per
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to include a mixture of incident and prevalent cases.
We were able to confirm that the observed increase
in prescription episodes arose because those who had
been followed for a longer period after the first episode
of depression had an increasing number of prescrip-
tion episodes over time.
Prescription duration
The data for prescription duration in the first year of
diagnosis show a small decrease in short term prescrip-
tions (<30days) from87.1%of all prescriptions in 1993
to 84.6% (in 2004(25 909/29 737 and 25 749/30 444,
respectively). The proportion of short term prescrip-
tions diminished with time from first year of diagno-
sis—for instance, to 77.8% after 5 years. Conversely,
the proportion of prescriptions for 31-60 days rose
from 12.3% in the year of diagnosis to 20.1% after
5 years.
Although the majority of prescriptions were for less
than 30 days (fig 4), the proportion of patients who
received such prescriptions decreased from 87.1% in
1993 to 78.2% in 2005 (25 909/29 737 and 155 360/
198 799, respectively). The reverse trend was seen in
the proportion of patients on a long duration prescrip-
tion, which increased slightly over the period of study.
The proportion of patients receiving a prescription for
31-60 days, for example, increased from12.3% in 1993
to 19.9% in 2005 (3668/29 737 and 39 539/198 779,
respectively), and the proportion on antidepressants
for 61-180 days went from 0.5% to 1.8% (151/29 737
and 3622/198 779). Again, this change is likely to arise
from a change in the nature of the cohort to include a
mixture of incident and prevalent cases.
Patterns of treatment received
Figure 5 shows the proportion of patients in each of the
five treatment pattern groups—chronic treatment,
intermittent treatment, short term treatment, delayed
treatment, and no treatment. Between 1993 and 2001
there was a small but steady increase in the proportion
of patients receiving intermittent treatment (34.8%
(4894/14 064) v 38.2% (5969/15 645)), together with a
small rise in those receiving chronic treatment (8.4%
(1181/14 064) v 10.2% (1597/15 645)). The proportion
of patients receiving short term treatment showed a
corresponding decrease (36.2% (5084/14 064) v
31.6% (4936/15 645)). The proportion receiving
delayed treatment or no treatment remained constant
at around 1% and 19%, respectively.
The average duration of individual prescriptions
over five years was roughly similar for each treatment
pattern group. As would be anticipated, the chronic
treatment group generally had slightly longer average
prescription duration (by 1-2 days).
Figure 6 shows that the chronic treatment group
received a higher number of prescriptions than any
other group—on average 35 prescriptions per patient
over five years—and, therefore, received the bulk of
the prescriptions numerically. There was also an
increase in the average number of prescriptions per
patient in the chronic treatment group: from 34 over
five years to 36 over five years in the period studied
which equates to approximately 60 days more treat-
ment over the five year period in 2001-5 compared to
1993-7. Bearing inmind the increase in the proportion
of patients in this group (from 8.4% to 10.2%), the
increase in the duration of prescriptions in the chronic
treatment group is responsible for a substantial
increase in the overall prescribing volume. A similar
pattern was seen in the other treatment groups, but
with a smaller impact on overall volumes.
Total prescription days
Table 1 shows the total number of prescription days
over the five years from first diagnosis for each of the
treatment pattern groups. The data show an overall
increase in prescription duration from just under 2.9
million days in the patients studied between 1993 and
1997 tomore than 4.3million days in the those studied
between 2001 and 2005. Chronic and intermittent pre-
scribing together accounted for approximately 90% of
the total prescriptions (for example, 270 005/288 249
in 1993). Although the number of prescription days
increased over time for all treatment groups, small
changes in the constitution of the chronic treatment
and intermittent treatment groups were responsible
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for most of the increase in antidepressant prescribing
over the duration of the study.
Total prescription days for each of the five treatment
pattern groups is summarised in figure 7. The volume
of prescriptions attributed to long term prescribing
(that is, the proportion of prescriptions in the chronic
and intermittent groups) contributed the majority of
the change in overall prescribing volume.
DISCUSSION
We have demonstrated that between 1993 and 2005,
there was overall a small change in the incidence of
new diagnoses of depression and a small increase in
the mean duration of the antidepressant prescription
for the first episode of depression. However, there
were more marked trends within age and sex, includ-
ing a large rise in the incidence of new diagnoses
among young women and, to a lesser extent, among
young men.
The majority of antidepressant prescriptions were
given as long term treatment or to patients with multi-
ple episodes of depression. Small increases both in the
proportion of patients in these groups and in the dura-
tion of prescriptions made to such individuals
accounted for a near doubling of the total volume of
antidepressant prescribing between 1993 and 2005.
Although the proportion of new cases initially treated
with antidepressants did rise slightly over this period,
changes in recognition, case definition, or duration of
initial prescription are unlikely to account for the dra-
matic increase in antidepressant prescribing. A key
question remains: if the changes in antidepressant pre-
scribing are accounted for by changes in the propor-
tions of those in receipt of long term prescriptions,
does this represent appropriate prescribing for those
with chronic and relapsingdisease according to current
guidance or does it arise from a failure to discontinue
antidepressants in those with milder illness, or both?
The majority of new episodes of depression were
associated with antidepressant prescribing in the year
of diagnosis (79%), similar to other studies.9 16 17 This
proportion remained remarkably stable over the per-
iod studied, falling only in the last two years.
Strengths and limitations of study
The data on both diagnosis and prescribing in the
GPRD are very reliable given the stability of the lists
of registered patients and the healthcare system. The
GPRD has no formal control on diagnostic categories
though, which are determined by individual general
practitioners. We did include all possible depression
diagnostic codes in our study, but cannot exclude the
possibility that some prescribing took place without
any appropriate depression code. Also, prescribing
records reflect the issue of prescriptions and not the
dispensing or taking of the medication. Although the
majority of prescribing takes place in primary care in
the UK, medication may also be prescribed in other
settings—for example, to hospital outpatients—but
this is likely to contribute little overall in the UK.
In this study we were principally interested in pat-
terns of prescribing rather than absolute numbers.
Although the data are observational and we were
unable to control for patient level confounders, we
believe that this large dataset does give valuable
insights into prescribing patterns in the UK. We can
be less confident regarding the generalisability of our
findings to other healthcare systems where anti-
depressant prescribing may not be so dominated by
primary care physicians.
We restricted the analysis to practices that contribu-
ted data to the GPRD throughout the whole study per-
iod. We thought that although patients can leave
individual practices, the stability provided by using
the 170 stable practiceswould allowgreater confidence
in interpretation of trends within the data. Including all
practices—some of which joined or left the database
over the study period—wouldmake trends in prescrib-
ingmore difficult to interpret. The question arises as to
whether the stable practices are representative of the
whole practice population. Various factors reassure
us that this is the case. Firstly, being a stable practice
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has no implications regarding the nature of the practice
itself; the label just indicates that the practice was con-
sistently contributing data that were regarded as up to
standard for the entire study period. Secondly, there
was no age or sex difference between the patients in
the stable practices and those in the whole cohort, nor
anymajor difference in diagnostic codes.We did iden-
tify that the incidence of depression appeared higher in
the whole cohort. This disparity possibly arose as a
result of incomplete data from some practices such
that some cases of prevalent depression were included
because of the absence of previous history codes.
Data that were entered into the GPRD system by
general practitioners in the participating clinics were
transferred to theGPRDorganisation in batches.How-
ever, the decision onwhen to proceedwith these trans-
fers was made entirely by the clinics themselves.
Hence, data collected close to the date on which we
extracted data for this study, February 2006, might
not contain the entire set from each clinic. This anom-
aly should only affect data from the final months of
2005 and is less likely to be a problem in the stable
practices. We elected to include these data because a
large number of observations were still available, and
the incompleteness of the data should only have mini-
mal effects on rates or proportions.
Comparison with other studies
Our data suggest that a small increase each year in the
numbers of patients receiving repeat prescriptions
accounts for a large increase in overall antidepressant
prescribing volumes. Some support for these findings
is found elsewhere in the literature.
In a Canadian study, the prevalence of new anti-
depressant prescriptions (defined in terms of no pre-
scribing in the previous two years) rose between 1998
and 1999 then fell in 2004,whereas prescribing for pre-
valent cases doubled over the eight year study.16 These
results are in accord with our findings and suggest that
changes in the duration of prescribing aremore impor-
tant in determining overall prescription numbers than
changes in the number of cases treated.
A US study similarly reported increased new pre-
scribing of antidepressants to outpatients between
1987 and 1997, although no data were available on
long term prescriptions.9 In another study, a cross sec-
tion of general practitioner case notes was examined
for patients on antidepressant prescriptions. The aver-
age duration of prescription was five to seven years
where the prescribing indication was for mental health
problems, suggesting that longer term prescribing
dominates.9 11 Other previous studies have concen-
trated on the initial prescribing decision.17-19
National policy in the UK has focused on targeting
antidepressants to patients with more severe symp-
toms by incentivising the use of questionnaire mea-
sures of severity before treatment through the UK
general practice quality and outcomes framework.20
A recent study of prescribing patterns following
initiation of the framework showed appropriate target-
ing of antidepressants.21 The proportion of patients
with a new diagnosis prescribed an antidepressant
(79%) was very similar to that in our study. This raises
the question of how much influence the use of ques-
tionnaires actually has on the prescribing decision. It
has already been established that patients are anxious
regarding discontinuation of antidepressants and
Table 1 | Antidepressant prescription days over five years from first diagnosis for the five treatment pattern groups
Treatment
pattern group
Total number
of patients
Five year follow-up from year of first diagnosis
1993-1997
1994-
1998
1995-
1999
1996-
2000
1997-
2001
1998-
2002
1999-
2003
2000-
2004 2001-2005
Number of
prescription
days
Number of
prescription
days
Number of
prescription
days
Number of
prescription
days
Number of
prescription
days
Number of
prescription
days
Number of
prescription
days
Number of
prescription
days
Number of
prescription
days
Chronic 13 783 1 239 600
(43.0%)
1 379 889
(42.6%)
1 493 335
(43.4%)
1 613 051
(43.6%)
1 783 114
(45.4%)
1 879 298
(45.4%)
1 927 921
(45.1%)
1 929 204
(44.1%)
1 868 183
(43.2%)
Intermittent 51 922 1 330 277
(46.2%)
1 518 176
(46.8%)
1 592 064
(46.3%)
1 704 929
(46.1%)
1 770 729
(45.1%)
1 855 608
(44.8%)
1 946 506
(45.6%)
1 998 799
(45.7%)
2 042 076
(47.2%)
Short term 47 761 271405(9.4%) 289552(8.9%) 313591(9.1%) 330177(8.9%) 314794(8.0%) 333402(8.1%) 337862(7.9%) 350289(8.0%) 350 149 (8.1%)
Delayed 1683 40 959 (1.4%) 54 578 (1.7%) 42 693 (1.2%) 52 321 (1.4%) 59 947 (1.5%) 70 471 (1.7%) 58 447 (1.4%) 92 548 (2.1%) 65 502 (1.5%)
None 26 613 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Total 141 762 2 882 241 3 242 196 3 441 682 3 700 477 3 928 584 4 138 779 4 270 736 4 370 839 4 325 910
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require support from their family doctor to stop
medication.22 Patients not reviewed and supported
are unlikely to initiate discontinuation on their own.
Long term prescribing is indicated for patients with
recurrent or relapsing depression.23 Long term pre-
scribing may, therefore, be appropriate and in line
with current guidelines.15 The observed changes in
antidepressant prescribingmay represent better adher-
ence to such guidelines. However, in one recent study
involving detailed case review of patients on longer
term antidepressant prescriptions, more than half of
those examined (56%) failed to meet criteria for a for-
mal psychiatric diagnosis.24 Independent case review
showed that there was no indication for continued
receipt of an antidepressant in nearly a third (31%) of
participants.24 In another study of long term anti-
depressant prescribing, there was no documented
mental health review over a two year period in 21%
of the case notes.11
Conclusions
Antidepressant prescribing is much higher compared
with 10 years ago. This increase is not because of an
increase in the incidence of new cases of depression, a
lower threshold for treatment, an increase in the pro-
portion of new cases of depression for whom anti-
depressants are prescribed, or an increase in the
duration of the prescriptions written for new cases of
depression. Rather, the dramatic changes in anti-
depressant prescribing volumes between 1993 and
2005 seem to be largely because more patients are on
long term medication and this group consumes the
most drugs. In order to better understand the rise in
antidepressant prescribing, research needs to focus
on chronic prescribing and policy needs to focus on
encouraging appropriate high quality monitoring and
review of those patients who become established on
long term prescriptions.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
The United Kingdom, along with other Western countries, has seen a substantial increase in
antidepressant prescribing over the past 20 years
The reasons behind this rise are not well understood but do not seem to include lower
thresholds for diagnosis or treatment, or changes in illness behaviour
WHAT THIS STUDY ADDS
The incidence of new cases of depression between 1993 and 2005 rose in young women but
fell slightly in other groups such that overall incidence declined slightly
Long term prescribing accounts for the majority of antidepressant prescriptions
The rise in antidepressant prescribing seems to be largely explained by a small increase in
long term prescribing
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